FDA delays abortion pill mifepristone safety review until March 2027

The U.S. Food and Drug Administration has announced that its safety review of the abortion pill mifepristone will continue into next year, with a final report expected by March 2027. The timeline, revealed in an October 2026 court filing for a Louisiana lawsuit, has angered anti-abortion advocates who accuse the Trump administration of slow-walking restrictions past the midterm elections. While the FDA analyzes data from 100,000 patients, mail-order access remains protected by the Supreme Court.

Details of the FDA safety review

• ▪The U.S. Food and Drug Administration is utilizing a statistical data mining method within its Sentinel distributed database to identify previously unknown safety concerns associated with mifepristone
• ▪The U.S. Food and Drug Administration is conducting its safety study of mifepristone by comparing side-effect frequencies among approximately 100,000 women who took mifepristone against a comparator group of women who underwent surgical abortions
• ▪The U.S. Food and Drug Administration announced in an October 7, 2026 court filing that it expects to complete its mifepristone safety review data collection by mid-December 2026, with a final report expected by March 2027

Backlash over the review timeline

• ▪Pro-life leaders expressed suspicion that the U.S. Food and Drug Administration is intentionally delaying its safety evaluation of mifepristone until after the November 3, 2026, midterm elections
• ▪Gavin Oxley of the anti-abortion group Americans United for Life criticized the FDA's March 2027 report timeline, stating that the Trump administration lacks true leadership and is uninterested in mitigating the harms of the abortion pill

Origins of the safety review

• ▪U.S. Health and Human Services Secretary Robert F. Kennedy Jr. commissioned a safety review of mifepristone after a conservative think tank claimed to have found high rates of serious complications from the drug
• ▪U.S. Health and Human Services Secretary Robert F. Kennedy Jr. and former Food and Drug Administration Commissioner Marty Makary previously pledged to study the safety of abortion pills

Ongoing litigation over mifepristone

• ▪The U.S. Supreme Court has blocked any changes to mifepristone regulations, maintaining nationwide access to the drug while the Louisiana v. FDA litigation and other state challenges proceed through the courts
• ▪The U.S. Food and Drug Administration provided its safety review timeline update in response to a court-ordered deadline in a lawsuit brought by the state of Louisiana, which alleges mail-order mifepristone undermines its state abortion ban

History of mifepristone approval and access

• ▪The U.S. Food and Drug Administration first approved mifepristone in 2000, and the drug has since become the most common method of abortion in the United States, accounting for 65% of all U.S. abortions in 2023
• ▪The U.S. Food and Drug Administration permanently eliminated the in-person dispensing requirement for mifepristone in 2023, allowing the drug to be prescribed online and delivered by mail

Debatable claims

• ▪Political considerations are the main driver of the FDA's delayed mifepristone review
• ▪The FDA's new safety review of mifepristone is scientifically warranted
• ▪The FDA's March 2027 timeline for its mifepristone safety review is justified
• ▪The FDA should immediately reinstate the in-person dispensing requirement for mifepristone